LIPS: Timing and Intensity of the Exposures and Attributable Burden of Acute Lung Injury

Sponsor
Mayo Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT00980915
Collaborator
(none)
6,600
1
144
45.8

Study Details

Study Description

Brief Summary

The purpose of the study is to identify the patients at high risk of developing Acute Lung Injury (ALI) at the time of hospital admission, and before intensive care unit admission.

Aim 1- To validate the prediction model (Lung Injury Prediction Score) in a population based sample of hospitalized patients.

Aim 2- To determine the significance of health-care related ALI risk modifiers in a population based sample.

Aim 3- To compare the short and long term outcomes between patients at high risk who do, and do not develop ALI.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Acute lung injury (ALI) is an example of a critical care syndrome with limited treatment options once the condition is fully established.Not surprisingly, many treatments targeting the mechanisms identified in preclinical studies have failed to improve patient outcomes.The most likely reason could be due to inadequate and delayed recognition of patients at risk and the subsequent development of the full blown syndrome.ALI/ARDS usually develops during the first hours of ICU admission, and often is the very reason for ICU admission.

    Clinical prediction models have been extensively used in the clinical practice to identify patients at high risks who may benefit from specific interventions. However, no such tool exists to predict the development of ALI in patients at risk. We have recently developed an ALI prediction model (Lung Injury Prediction Score:LIPS)which incorporates demographic, environmental and clinical characteristics at the time of, and before, hospital admission. If validated, this model will serve to find the population of patients at high risk of ALI in whom future prevention trials will be conducted. By determining not only patients at high risk but also the attributable burden of ALI/ARDS in contemporary cohorts of patients at risk, our findings will facilitate the prioritization of preventive strategies and future clinical trials.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    6600 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Identifying Patients at Risk of Developing Acute Lung Injury at the Time of Hospital Admission:Toward the Prevention of Acute Lung Injury (ALI)
    Study Start Date :
    Dec 1, 2008
    Actual Primary Completion Date :
    Dec 1, 2020
    Actual Study Completion Date :
    Dec 1, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    At risk for Acute Lung Injury

    Controls-High risk patients at risk of Acute Lung Injury(ALI) but do not develop ALI Cases-High risk patients that do develop Acute Lung Injury

    Outcome Measures

    Primary Outcome Measures

    1. Development of ALI [During the hospital stay (before discharge and maximum of 30 days)]

    Secondary Outcome Measures

    1. Quality adjusted survival [6 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All Olmsted County residents more than 18 years of age who were admitted to the two Mayo Clinic Rochester hospitals
    Exclusion Criteria:
    • Denied the use of medical records for research

    • Acute lung injury or pulmonary edema already present at the time of hospital admission

    • Admitted for comfort or hospice care only

    • Children

    • Hospital readmission

    • Patients admitted for cardiac telemetry, coronary care unit, low risk elective surgeries, labor and delivery

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mayo Clinic Rochester Minnesota United States 55905

    Sponsors and Collaborators

    • Mayo Clinic

    Investigators

    • Principal Investigator: Ognjen Gajic, M.D., Mayo Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Ognjen Gajic, Ognjen Gajic, M.D., Mayo Clinic
    ClinicalTrials.gov Identifier:
    NCT00980915
    Other Study ID Numbers:
    • 08-003560
    • LIPSSTUDY
    First Posted:
    Sep 21, 2009
    Last Update Posted:
    Feb 5, 2021
    Last Verified:
    Feb 1, 2021

    Study Results

    No Results Posted as of Feb 5, 2021